Lumican modulates adipocyte function in obesity-associated type 2 diabetes

Obesity-associated type 2 diabetes (DM) leads to adipose tissue dysfunction. Lumican is a proteoglycan implicated in obesity, insulin resistance (IR), and adipocyte dysfunction. Using human visceral adipose tissue (VAT) from subjects with and without DM, we studied lumican effects on adipocyte funct...

Descripción completa

Detalles Bibliográficos
Autores principales: Strieder-Barboza, Flesher, Carmen G., Geletka, Lynn M., Eichler, Tad, Akinleye, Olukemi, Ky, Alexander, Ehlers, Anne P., Lumeng, Carey N., O’Rourke, Robert W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Taylor & Francis 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9728465/
https://www.ncbi.nlm.nih.gov/pubmed/36457256
http://dx.doi.org/10.1080/21623945.2022.2154112
Descripción
Sumario:Obesity-associated type 2 diabetes (DM) leads to adipose tissue dysfunction. Lumican is a proteoglycan implicated in obesity, insulin resistance (IR), and adipocyte dysfunction. Using human visceral adipose tissue (VAT) from subjects with and without DM, we studied lumican effects on adipocyte function. Lumican was increased in VAT and adipocytes in DM. Lumican knockdown in adipocytes decreased lipolysis and improved adipogenesis and insulin sensitivity in VAT adipocytes in DM, while treatment with human recombinant lumican increased lipolysis and impaired insulin-sensitivity in an ERK-dependent manner. We demonstrate that lumican impairs adipocyte metabolism, partially via ERK signalling, and is a potential target for developing adipose tissue-targeted therapeutics in DM.

Ejemplares similares